H
HLS
vs
S
S&P/ASX 300
Over the past 12 months, HLS has underperformed S&P/ASX 300, delivering a return of -44% compared to S&P/ASX 300's +1% growth.
Stocks Performance
HLS vs S&P/ASX 300
Performance Gap
HLS vs S&P/ASX 300
Performance By Year
HLS vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Healius Ltd
Glance View
Healius is an Australian medical diagnostics company. It mainly earns money by running pathology services, which means collecting patient samples and testing them in labs for doctors, hospitals, and other healthcare providers. It also has interests in related diagnostic services, so it sits behind the scenes as part of the healthcare testing process rather than as a hospital or doctor group. Its customers are mostly patients referred by general practitioners, specialists, and hospitals, plus healthcare providers that need reliable lab results for treatment decisions. Healius makes money when those tests are processed and billed through healthcare funding systems, insurer arrangements, or direct patient payments depending on the service. What makes the business easy to understand is that it is a volume-based diagnostics provider with a large network of collection points and laboratories. The key value is speed, accuracy, and reach: Healius helps move samples from clinics and hospitals into lab results that doctors use to diagnose illness, monitor treatment, and make decisions.
